Also known as:BPC· community shorthandBody Protection Compound 157· expanded name
Musculoskeletal injurygastrointestinal and wo…
BPC-157
Evidence levelPreclinical-heavy
Human evidenceExtremely limited
Regulatory statusNot FDA-approved
What you need to know in 20 seconds
What is it?
Synthetic 15-amino-acid peptide
Research focus
Musculoskeletal injury, gastrointestinal and wound-healing research
Human evidence
Human evidence remains extremely limited. A 2025 systematic review found 35 preclinical studies and only one clinical study; a later retrospective real-world preprint cannot establish efficacy. GI and injury-healing claims remain dominated by animal/preclinical research.
Regulatory status
Not FDA-approved; FDA has highlighted safety-information gaps for compounded BPC-157.
Main limitations
Efficacy for injury healing in humans, optimal route, long-term safety and benefit-risk are not established.
Safety
Human safety is poorly characterised; FDA highlights potential immunogenicity, peptide impurities and limited safety information.
i
Human evidence remains extremely limited. A 2025 systematic review found 35 preclinical studies and only one clinical study; a later retrospective real-world preprint cannot establish efficacy. GI and injury-healing claims remain dominated by animal/preclinical research.
What the evidence actually supports
✓Present as a preclinical hypothesis, not a proven healing therapy.
✓Human safety remains uncharacterised despite online claims of safety.
✓Keep GI claims separate from the limited human musculoskeletal/safety literature.
What is not established / key limitations
×No controlled human tendon-healing trial identified; knee evidence is retrospective/self-reported.
×No meaningful long-term or powered safety dataset.
×No established controlled human therapeutic efficacy for GI healing.
Selected study & evidence records
Intra-articular BPC-157 for multiple types of knee pain
2021 · Retrospective observational report · n=17
Among 16 contacted patients, 11/12 receiving BPC-157 alone reported significant improvement; uncontrolled and subjective.
Human safety is poorly characterised; FDA highlights potential immunogenicity, peptide impurities and limited safety information.
Human safety is poorly characterised; FDA highlights potential immunogenicity, peptide impurities and limited safety information.
Technical details
Mechanism / biologyProposed effects involve angiogenic, nitric-oxide, inflammatory and tissue-repair signalling; exact human mechanism is unestablished.
Route / formulation boundaryResults from animal models cannot be presented as proven human healing effects. Research-grade product quality varies.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusHuman pilot regimen verified. A two-participant IV safety pilot used 10 mg on day 1 and 20 mg on day 2 as one-hour infusions. This does not establish an effective, subcutaneous or long-term human dose.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
